Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
Status:
Completed
Trial end date:
2020-01-22
Target enrollment:
Participant gender:
Summary
To assess treatment effectiveness and safety of oral crizotinib administered to East Asian
patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive
for a ROS1 positive gene mutation (translocation or inversion) and confirmed negative for an
ALK mutation